News

Article

Sponsored Content

Exploring best-practice manufacturing strategies for highly potent oral solid dosage forms

As the number of highly potent oral solid dose (HPOSD) drugs in development and on the market increases, so are regulator’s expectations regarding their safe manufacture. In this white paper Pfizer CentreOne examines what developers and their manufacturing partners need to know about its unique regulatory challenges and how to navigate HPOSD’s complex manufacturing environment successfully.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Content
Site Logo
August 2nd 2025

The Roadmap to Asset Performance Management in Life Science

BlueMountain
Site Logo
August 2nd 2025

Unlock the Future of Enterprise Asset Management with Agentic AI

BlueMountain
Site Logo
August 2nd 2025

From Maintenance to Compliance: A Guide to CMMS/EAM Readiness

BlueMountain
Site Logo
August 2nd 2025

Executive Summary: End-To-End Regulatory CDMO Solutions: Development, Manufacturing, and Approval

Lonza
The road to market access is long and complex. Choosing a CDMO with experienced staff can prove vital to success. In this executive summary, Praveenkumar Devakadaksham and Dr. Roché Marcel Walliser explain all the ways they help make the journey from pharmaceutical development to commercial distribution as smooth as possible. Learn more about:
Site Logo
August 2nd 2025

Executive Summary: Keys to Supplying Decentralized Trials: The Value of Direct-to-Patient Solutions and the Pharmacy-Led Model

Catalent
Site Logo
August 2nd 2025

Innovations in Pregastric Absorption Drug Delivery & Orally Disintegrating Tablets

Catalent